Appeal to Israel Supreme Court concerning Fosamax rejected.
Gilead drops patent suit against Teva, allowing Teva to enter market with a generic Version of Viread at the end of 2017.
The Canadian Supreme Court has accepted Teva’s contention that Pfizer’s patent for Viagra is invalid opening the way for Teva and others to produce and distribute generic versions of the drug. The Canadian ruling may be found here The reason that… Read More ›
Yeda, the Tech Transfer Company of the Weizmann Institute has a patent for glatiramer acetate which is exclusively licensed to Teva. The pharmaceutical is marketed as Copaxone and used to treat multiple schlerosis (MS). Mylan challenged the validity of the European patent EP 07862888 which,… Read More ›
Validity of Teva’s patents for Copaxone challenged in US court
Israel Patent Office refuses patent for increased solubility of tadalafil, despite opposer withdrawing opposition.
The Supreme Court of Canada has announced that it would hear Teva Canada Ltd.’s challenge to Pfizer Inc.’s patent for Viagra. The high court granted Teva Canada’s leave to appeal without comment Thursday, agreeing to review a September 2010 ruling from Canada’s… Read More ›